Drug Trial Radar · NCT00279448
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Dec 23, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,779
Actual
Start
Jan 2002
Primary completion
Nov 2008
Study completion Jun 2009
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 19, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare recurrence free survival between two treatment groups (5 years with exemestane vs 2.5 to 3 years tamoxifen followed by 2 to 2.5 years of exemestane for a total duration of 5 years) This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted. Link to TEAM Trial \[971-ONC-0028-081/A5991026\] Study Results: http://clinicaltrials.gov/ct2/show/results/NCT00036270?term=971-ONC-0028-081\&rank=1
Conditions
- Breast Neoplasms
Interventions
exemestaneDrug
On tablet of 25 mg per day during 5 years
tamoxifenDrug
Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare recurrence free survival between two treatment groups.Time frame: 2.75 years and 5 years
Locations
59 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Aix-en-Provence, France
Pfizer Investigational Site
Amiens, France
Pfizer Investigational Site
Annecy, France
Pfizer Investigational Site
Avignon, France
Pfizer Investigational Site
Bayonne, France
Pfizer Investigational Site
Blois, France
Pfizer Investigational Site
Bordeaux, France
Pfizer Investigational Site
Bordeaux, France
Pfizer Investigational Site
Brest, France
Pfizer Investigational Site
Cagne Sur Mer, France
Pfizer Investigational Site
Chalon-sur-Saône, France
Pfizer Investigational Site
Chaumont, France
Pfizer Investigational Site
Croix, France
Pfizer Investigational Site
Dijon, France
Pfizer Investigational Site
Douai, France
Pfizer Investigational Site
Draguignan, France
Pfizer Investigational Site
Dunkirk, France
Pfizer Investigational Site
Évreux, France
Pfizer Investigational Site
Hyres, France
Pfizer Investigational Site
L'Union, France
Pfizer Investigational Site
Le Havre, France
Pfizer Investigational Site
Lille, France
Pfizer Investigational Site
Lorient, France
Pfizer Investigational Site
Lyon, France
Pfizer Investigational Site
Mareuil-lès-Meaux, France
Pfizer Investigational Site
Marseille, France
Pfizer Investigational Site
Marseille, France
Pfizer Investigational Site
Marseille, France
Pfizer Investigational Site
Metz, France
Pfizer Investigational Site
Montauban, France
Pfizer Investigational Site
Montbéliard, France
Pfizer Investigational Site
Montélimar, France
Pfizer Investigational Site
Montpellier, France
Pfizer Investigational Site
Mougins, France
Pfizer Investigational Site
Nancy, France
Pfizer Investigational Site
Nantes, France
Pfizer Investigational Site
Neuilly, France
Pfizer Investigational Site
Nice, France
Pfizer Investigational Site
Nîmes, France
Pfizer Investigational Site
Paris, France
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.